Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer

Allen Y Chen^{1

2}, Jedd D Wolchok^{2

3}, Anne R Bass^{4

5}

Affiliations

¹ Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA.
² Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
³ Human Oncology and Pathogenesis Program, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA. bassa@hss.edu.
⁵ Department of Medicine, Weill Cornell Medicine, New York, NY, USA. bassa@hss.edu.

Comment

Allen Y Chen et al. Nat Rev Rheumatol. 2021 Sep.

. 2021 Sep;17(9):577-578.

doi: 10.1038/s41584-021-00654-7. Epub 2021 Jul 5.

Allen Y Chen^{1

2}, Jedd D Wolchok^{2

3}, Anne R Bass^{4

5}

¹ Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA.
² Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
³ Human Oncology and Pathogenesis Program, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA. bassa@hss.edu.
⁵ Department of Medicine, Weill Cornell Medicine, New York, NY, USA. bassa@hss.edu.

No abstract available

Comment on

TNF in the era of immune checkpoint inhibitors: friend or foe?
Chen AY, Wolchok JD, Bass AR. Chen AY, et al. Nat Rev Rheumatol. 2021 Apr;17(4):213-223. doi: 10.1038/s41584-021-00584-4. Epub 2021 Mar 8. Nat Rev Rheumatol. 2021. PMID: 33686279 Free PMC article. Review.
Combining TNF blockade with immune checkpoint inhibitors in patients with cancer.
Montfort A, Virazels M, Colacios C, Meyer N, Ségui B. Montfort A, et al. Nat Rev Rheumatol. 2021 Sep;17(9):577. doi: 10.1038/s41584-021-00653-8. Nat Rev Rheumatol. 2021. PMID: 34226729 No abstract available.

1. Montfort, A. et al. Combining TNF blockade with immune checkpoint inhibitors in patients with cancer. Nat. Rev. Rheumatol. https://doi.org/10.1038/s41584-021-00653-8 (2021). - DOI - PubMed
1. Chen, A. Y., Wolchok, J. D. & Bass, A. R. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat. Rev. Rheumatol. 17, 213–223 (2021). - DOI
1. Montfort, A. et al. Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial. Clin. Cancer Res. 27, 1037–1047 (2021). - DOI
1. Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019). - DOI